DYNHealthcareMid-Cap

Dyne Therapeutics, Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Dyne Therapeutics, Inc. (DYN), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are DYN insiders buying or selling?

Dyne Therapeutics, Inc. insiders reported 15 open-market buys ($93.6M) and 190 sells ($417.0M) across 205 Form 4 filings — a net selling position of $323.4M.

Source: SEC EDGAR Form 4

Key Statistics (as of Aug 17, 2026)

Total Form 4 filings
205
SEC EDGAR
Insider filers
20
Insider buys (15)
$93.6M
Insider sells (190)
$417.0M

Insider sentiment

Net selling

Net insider flow of $323.4M in net selling. 1 insider buy in the last 90 days.

Recent DYN insider transactions

DateInsiderRoleTypeSharesPriceValue
Aug 17, 2026Jason P RhodesDirectorSale2.6M$25.20$65.2M
Aug 17, 2026Johanna Friedl-NadererChief Commercial OfficerSale226$26.28$5.9K
Aug 17, 2026Douglas KerrChief Medical OfficerSale1.6K$26.28$40.9K
Aug 17, 2026John CoxCEO & PresidentSale5.0K$26.28$131.0K
Aug 17, 2026Erick LuceraChief Financial OfficerSale1.8K$26.28$47.2K
Jul 29, 2026Dirk KerstenDirectorSale261.5K$25.51$6.7M
Jul 8, 2026Jason P RhodesDirectorSale777.5K$22.97$17.9M
Jun 30, 2026Jason P RhodesDirectorSale504.7K$21.23$10.7M
Jun 26, 2026Erick LuceraChief Financial OfficerSale2.4K$20.37$48.1K
Jun 26, 2026Jason P RhodesDirectorSale267.8K$21.09$5.6M
Jun 24, 2026Dirk KerstenDirectorSale264.0K$20.70$5.5M
Jun 22, 2026Dirk KerstenDirectorSale84.4K$20.10$1.7M
Jun 17, 2026Douglas KerrChief Medical OfficerSale887$18.33$16.3K
Jun 17, 2026Johanna Friedl-NadererChief Commercial OfficerSale145$18.33$2.7K
Jun 17, 2026John CoxCEO & PresidentSale2.7K$18.33$49.2K
Jun 9, 2026Brian S PosnerDirectorPurchase2.0K$16.94$33.9K
Jun 5, 2026Brian S PosnerDirectorPurchase2.5K$17.48$43.7K
May 28, 2026Brian S PosnerDirectorPurchase2.0K$18.21$36.4K
May 22, 2026Brian S PosnerDirectorPurchase2.5K$17.12$42.8K
May 14, 2026Johanna Friedl-NadererChief Commercial OfficerSale228$18.36$4.2K
May 14, 2026Douglas KerrChief Medical OfficerSale1.6K$18.36$28.7K
May 14, 2026Erick LuceraChief Financial OfficerSale1.4K$18.36$26.6K
May 14, 2026John CoxCEO & PresidentSale3.3K$18.36$60.8K
May 6, 2026Jason P RhodesDirectorSale106.7K$18.14$1.9M
Apr 30, 2026Jason P RhodesDirectorSale227.3K$18.38$4.2M

Showing the 25 most recent of 205 Form 4 filings for Dyne Therapeutics, Inc..

Most active DYN insiders

  • Dirk Kersten33 filings
  • Richard William Scalzo26 filings
  • Oxana Beskrovnaya22 filings
  • Susanna Gatti High19 filings
  • Jonathan Mcneill18 filings

Ask anything about DYN insider activity

Use Trabud's AI agent to query Dyne Therapeutics, Inc.'s Form 4 history in plain English — "Show me DYN CEO purchases this year" or compare it against any other ticker.

Open the AI agent

DYN insider trading FAQ

Are Dyne Therapeutics, Inc. insiders buying or selling?

Across 205 SEC Form 4 filings, Dyne Therapeutics, Inc. (DYN) insiders reported 15 open-market purchases totaling $93.6M and 190 sales totaling $417.0M. That is a net selling position of $323.4M.

How many insiders trade DYN stock?

20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Dyne Therapeutics, Inc.. The most recent filing was accepted on Aug 17, 2026.

Where does Trabud get DYN insider trading data?

All DYN insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content